News

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

To evaluate safety and tolerability of treatment with ACTengine® IMA203/IMA203CD8 products as monotherapy or in combination with nivolumab

News

Relapsed/Refractory Multi-Center, Open-Label, Phase I/II Clinical Trial To Evaluate The Safety And Anti-Tumor Activity Of Ab-101 Monotherapy - Clinical Trial

This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or ...

News

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer - Clinical Trial

This is a prospective, phase II, single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.

News

Dose Attenuated Chemotherapy in Compromised Patients with Lung Cancer - Clinical Trial

The purpose of this research study is to determine whether specific, planned adjustments to the doses of the drugs before you receive the first dose will make receiving treatment easier (that is to say, fewer side effects) while keeping ...

News

Study of LP-184 in Patients With Advanced Solid Tumors - Clinical Trial

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available.